Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Shuhang Wang"'
Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution
Autor:
Huiyao Huang, Yu Tang, Dawei Wu, Xinyu Meng, Shuhang Wang, Jun Wang, Yue Yu, Yuan Fang, Hong Fang, Qi Zhu, Ning Li, Binghe Xu, Yan Sun, Jie He
Publikováno v:
BMC Geriatrics, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Older adults are a growing segment of oncology population in China and beyong. However, older cancer patients were vastly underrepresented in clinical trial. To facilitate that all patients with cancer have equal access to the cut
Externí odkaz:
https://doaj.org/article/e6c0df4350194f3298e0e3fafc53fabf
Autor:
Huiyao Huang, Huilei Miao, Jun Wang, Dawei Wu, Qi Lei, Shuhang Wang, Hong Fang, Yu Tang, Ning Li, Binghe Xu, Jie He
Publikováno v:
Journal of the National Cancer Center, Vol 1, Iss 4, Pp 147-152 (2021)
Objectives: To describe and compare the research and development (R&D) pipeline of cancer new drugs and newly approved drugs in China and the USA in 2020, thus to provide decision-making evidence for related stakeholders. Methods: Clinical trials and
Externí odkaz:
https://doaj.org/article/d8b2537297774b9ca2ba38c8b3a18a4a
Autor:
Shuhang Wang, Qiuyan Yang, Lan Deng, Qi Lei, Yuqi Yang, Peiwen Ma, Yuxin Men, Bryant C. Yung, Robert J. Lee, Mengzi Zhang, Ning Li
Publikováno v:
Drug Discovery Today. 27:1236-1250
The use of expedited approval pathways for anticancer drug development, which provide the advantages of high efficiency and cost-effectiveness, has expanded significantly in recent years. During the past decade, a total of 410 new molecular entities
Autor:
Shuhang Wang, Dawei Wu, Jun Wang, Hong Fang, Jie He, Huiyao Huang, Ning Li, Yu Tang, Hui-lei Miao, Binghe Xu, Qi Lei
Publikováno v:
Journal of the National Cancer Center, Vol 1, Iss 4, Pp 147-152 (2021)
Objectives: To describe and compare the research and development (R&D) pipeline of cancer new drugs and newly approved drugs in China and the USA in 2020, thus to provide decision-making evidence for related stakeholders. Methods: Clinical trials and
Publikováno v:
Frontiers in immunology. 13
Cell therapy is a distinguished targeted immunotherapy with great potential to treat solid tumors in the new era of cancer treatment. Cell therapy products include genetically engineered cell products and non-genetically engineered cell products. Sev
Autor:
Yuqi Yang, Shuhang Wang, Peiwen Ma, Yale Jiang, Keman Cheng, Yue Yu, Ning Jiang, Huilei Miao, Qiyu Tang, Funan Liu, Yan Zha, Ning Li
Publikováno v:
Cancer Letters. 552:215969
Drug conjugates are conjugates comprising a tumor-homing carrier tethered to a cytotoxic agent via a linker that are designed to deliver an ultra-toxic payload directly to the target cancer cells. This strategy has been successfully used to increase
Publikováno v:
Genes & Diseases
Genes and Diseases, Vol 9, Iss 1, Pp 245-251 (2022)
Genes and Diseases, Vol 9, Iss 1, Pp 245-251 (2022)
TP53 mutations was reported to be correlated to the efficacy of program death-1 (PD-1) and program death ligand-1 (PD-L1). The role of co-mutations of TP53 with other recurrently mutated genes in outcome of anti-PD-(L)1 treatment for non-small cell l
Autor:
Ning Li, Yan Zha, Yuqi Yang, Shuhang Wang, Peiwen Ma, Qiyu Tang, Yandong Li, Yuan Fang, Qi Zhu, Wei Tao
Publikováno v:
Current cancer drug targets. 22(2)
Background: Rare solid tumors have attracted much more attention due to the great unmet clinical need, limited treatment options, and poor prognosis. As the most thoroughly studied tumor marker, carcinoembryonic antigen (CEA) can not only overexpress
Autor:
Zicheng Yu, Andy Q. Yuan, Hong Fang, Peiwen Ma, Qi Zhu, Ning Jiang, Shujun Xing, Yingjie Nie, Kun Chen, Youwei Jiang, Qi Lei, Yong Zhao, Shuhang Wang, Shujun Sun, Yuan Fang, Wei Tao, Minghui Zhang, Hui-lei Miao, Ning Li
Publikováno v:
EMBO Molecular Medicine
EMBO Molecular Medicine, Vol 13, Iss 9, Pp n/a-n/a (2021)
EMBO Molecular Medicine, Vol 13, Iss 9, Pp n/a-n/a (2021)
Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treati
Autor:
Ning Li, Jingwei Sun, Shuhang Wang, Zicheng Yu, Kun Chen, Qi Lei, Yarong Liu, Shujun Sun, Peiwen Ma, Zhongzheng Cao, Shujun Xing
Publikováno v:
BMC Medicine
BMC Medicine, Vol 19, Iss 1, Pp 1-7 (2021)
BMC Medicine, Vol 19, Iss 1, Pp 1-7 (2021)
Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients. Its diverse TCR clonality, superior